Advertisement


Lisa A. Carey, MD, on HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies

2021 San Antonio Breast Cancer Symposium

Advertisement

Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center, discusses findings from a pooled analysis of the MONALEESA-2, -3, and -7 trials. Among the findings was a consistent overall survival benefit with ribociclib plus endocrine therapy for patients with luminal A, luminal B, and HER2E breast cancer subtypes. Patients with the basal-like subtype did not derive a benefit from ribociclib, but the sample size was small (Abstract GS1-04).



Related Videos

Breast Cancer
Genomics/Genetics

Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life

Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).

Breast Cancer

Banu Arun, MD, on Fine-Tuning Risk Assessment and Risk Reduction in Breast Cancer

Banu Arun, MD, of The University of Texas MD Anderson Cancer Center, discusses a session she moderated that included discussion of how exercise and diet may reduce the risk of breast cancer, and emerging non-endocrine treatments that may help prevent the disease.

Breast Cancer

Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment

Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early breast cancer. Dr. Gnant also talks about whether any correlative studies hint at patient subgroups that this regimen may benefit (Abstract GS1-07) .

Breast Cancer
Immunotherapy

Peter Schmid, MD, PhD, on Early-Stage Triple-Negative Breast Cancer: Neoadjuvant Treatment With Pembrolizumab and Chemotherapy

Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).

Breast Cancer

François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Endocrine Therapy and Palbociclib

François-Clément Bidard, MD, PhD, of the Institut Curie, discusses phase III findings of the PADA-1 study, which showed that optimizing endocrine therapy after detecting the ESR1 mutation in patients with hormone receptor–positive, HER2-negative metastatic breast cancer may double their median progression-free survival (Abstract GS3-05).

Advertisement

Advertisement




Advertisement